TIAA Trust National Association Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• TIAA Trust National Association significantly increased its stake in Regeneron Pharmaceuticals by 1,187.4% during the first quarter, now owning 26,018 shares valued at approximately $16.5 million.
• Brokerages have varying ratings on Regeneron, with a consensus rating of "Moderate Buy" and an average price target of $837.61.
• Regeneron Pharmaceuticals recently declared a quarterly dividend of $0.88 per share, reflecting an annualized yield of 0.6% and a payout ratio of 8.96%.

TIAA Trust National Association boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,187.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,018 shares of the biopharmaceutical company's stock after buying an additional 23,997 shares during the quarter. TIAA Trust National Association's holdings in Regeneron Pharmaceuticals were worth $16,501,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Curat Global LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, American National Bank & Trust purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $44,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on REGN. Morgan Stanley reissued an "overweight" rating on shares of Regeneron Pharmaceuticals in a report on Friday. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Royal Bank Of Canada downgraded shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a research note on Friday, May 30th. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Trading Up 2.5%

NASDAQ:REGN opened at $558.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a fifty day simple moving average of $538.05 and a 200-day simple moving average of $603.39. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $60.34 billion, a P/E ratio of 14.08, a PEG ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.